
Overview
Background
Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).
Availability
- Dr Andy Moore is:
- Not available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
- Doctor of Philosophy, University College London
Research interests
-
Acute Myeloid Leukaemia
-
Leukaemia
-
Blood Cancers
-
Paediatric Oncology
-
Childhood Cancer
-
Biobanking
Works
Search Professor Andy Moore’s works on UQ eSpace
2012
Journal Article
A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay
Norris, R. L. G., Paul, M., George, R., Moore, A., Pinkerton, R., Haywood, A. and Charles, B. (2012). A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay. Journal of Chromatography B, 898, 136-140. doi: 10.1016/j.jchromb.2012.04.003
2011
Journal Article
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach
Moore, Andrew S., Norris, Ross, Price, Gareth, Nguyen, Thu, Ming, Ni, George, Rani, van Breda, Karin, Duley, John, Charles, Bruce and Pinkerton, Ross (2011). Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. Journal of Paediatric and Child Health, 47 (12), 875-882. doi: 10.1111/j.1440-1754.2011.02103.x
2011
Journal Article
Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia
Podesta, Jennifer E., Sugar, Richard, Squires, Matt, Linardopoulos, Spiros, Pearson, Andrew D. J. and Moore, Andrew S. (2011). Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research, 35 (9), 1273-1275. doi: 10.1016/j.leukres.2011.05.022
2011
Conference Publication
Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients
Lobb, M., Norris, R. L. G., Charles, B., Gilshenan, K., Moore, A. and Pinkerton, R. (2011). Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients. 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Stuttgart, Germany, 2-6 October, 2011. Philadelphia PA, United States: Lippincott Wiliams & Wilkins. doi: 10.1097/01.ftd.0000400651.94145.ba
2011
Conference Publication
Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736
Moore, AS, Faisal, A, Bavetsias, V, de Castro, DG, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Pearson, ADJ, Workman, P, Blagg, J, Raynaud, FI, Eccles, SA and Linardopoulos, S (2011). Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego CA, DEC 10-13, 2011.
2010
Journal Article
Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
Moore, A. S., Blagg, J., Linardopoulos, S. and Pearson, A. D. J. (2010). Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia, 24 (4), 671-678. doi: 10.1038/leu.2010.15
2010
Conference Publication
Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.
Podesta, JE, Griffin, MJ, Sugar, R, Squires, MS, Boddy, A, Linardopoulos, S, Pearson, ADJ and Moore, AS (2010). Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.
2010
Conference Publication
Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo
Moore, AS, Faisal, A, Bavetsias, V, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Raynaud, FI, Workman, P, Pearson, ADJ, Blagg, J, Eccles, SA and Linardopoulos, S (2010). Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.
2009
Journal Article
Vincristine: Can its therapeutic index be enhanced?
Moore, Andrew and Pinkerton, Ross (2009). Vincristine: Can its therapeutic index be enhanced?. Pediatric Blood and Cancer, 53 (7), 1180-1187. doi: 10.1002/pbc.22161
2009
Journal Article
Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva
Moore, Andrew S., Wilson, Peter G., McKelvie, Penny, La Nauze, Jamie and Hirst, Lawrence W. (2009). Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva. Pediatric Blood and Cancer, 53 (4), 669-671. doi: 10.1002/pbc.22062
2009
Journal Article
Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group
Moore, A.S., Shaw, P.J., Hallahan, A.R., Carter, T, Kilo, T, Nivison-Smith, I, O'Brien, T.A., Tapp, H, Teague, L, Wilson, S.R. and Tiedemann, K (2009). Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Medical Journal of Australia, 190 (3), 121-125.
2008
Conference Publication
Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience
Moore, A.S. and Hallahan, A.R. (2008). Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience. 48th Annual Scientific Meeting of the British Society for Haematology, Glasgow, Scotland, 7-9 April 2008. United Kingdom: Wiley-Blackwell Publishing Ltd.. doi: 10.1111/j.1365-2141.2008.07061.x
2007
Journal Article
Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids
Moore, A, Suppiah, R and Weier, S (2007). Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids. Journal of Paediatrics And Child Health, 43 (5), 415-416. doi: 10.1111/j.1440-1754.2007.01094.x
2007
Conference Publication
Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?
Moore, Andrew, Charles, Bruce, Wilkinson, Catherine, Weier, Steven and Pinkerton, Ross (2007). Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?. 39th Annual Conference of the International Society of Paediatric Oncology SIOP 2007, Mumbai, India, 31 October-3 November 2007. Hoboken: Wiley-Liss, Inc. doi: 10.1002/pbc.21342
Supervision
Availability
- Dr Andy Moore is:
- Not available for supervision
Supervision history
Completed supervision
-
2020
Doctor Philosophy
Characterisation of the MLL fusion transcriptome in childhood leukaemia
Principal Advisor
-
Doctor Philosophy
Aminopeptidase Inhibition as a Potential Therapeutic Strategy for Acute Myeloid Leukaemia
Principal Advisor
Media
Enquiries
Contact Dr Andy Moore directly for media enquiries about:
- Childhood Cancer
- Childhood Leukaemia
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: